BioVentix PLC Board Appointment (8774A)

TIDMBVXP

RNS Number : 8774A

BioVentix PLC

30 May 2023

Bioventix plc

("Bioventix" or the "Company")

Board Appointment

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics is delighted to announce that it has appointed Joanne (Jo) Pisani to the Board, as an independent Non-Executive Director, with immediate effect. Jo will chair the Company's Audit Committee.

Jo is a chartered engineer with a distinguished background in the Pharmaceutical, Life Sciences and Biotech sectors. She has held roles at GSK and BP in strategy, commercial and operational functions before working in strategic consultancy. She led PwC's UK Pharmaceutical and Life Sciences practice, assisting clients with developing strategy, designing and implementing transformational change and completing M&A transactions.

Jo is a passionate supporter of critical public health issues, such as tackling dementia, rare diseases and anti-microbial resistance. She focuses on supporting charities, universities and business start-ups. She is chair of Birmingham's Precision Health Technology Accelerator and also chairs the Advisory Board for London's MedCity. She serves on the boards of the UK Dementia Research Institute, LifeArc, The RSA Group, London and Partners and Beacon. She is also a Non-Executive Director and strategic advisor to biotech companies in the UK, Finland and Spain

Ian Nicholson, Chairman, commented: "The Board is delighted to welcome Jo to Bioventix. She brings considerable leadership and strategic experience in Life Sciences and biotech businesses, large and small, that is highly relevant to Bioventix and the opportunities being addressed by the Company. I am confident that she will add considerable value to the Company."

For further information please contact:

 
 Bioventix plc                                         Tel: [phone] 
  Peter Harrison             Chief Executive Officer 
  Bruce Hiscock              Chief Financial Officer 
 
 finnCap Ltd                                           Tel: [phone] 
  Geoff Nash/Simon Hicks     Corporate Finance 
  Alice Lane                 ECM 
 

Regulatory disclosures

INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G) OF THE AIM RULES FOR COMPANIES ("AIM RULES")

 
Full name:                                Joanne (Jo) Patra Pisani 
Age:                                      58 
Shareholding in the Company:              No shares held 
Current directorships and partnerships: 
                                            UK DRI Ltd 
                                            Beacon: for rare diseases 
                                            Ltd 
                                            LAM Action 
                                            LifeArc 
                                            London & Partners Limited 
                                            PHTA Ltd 
                                            Ostique Limited 
                                            Adora Digital Health Ltd 
                                            Elem Biotech SL 
                                            Aplagon Oy 
                                            RSA (Holdings) Ltd 
                                            MedCity Ltd 
Historic directorships and partnerships   Karoo CGT Limited 
 in previous 5 years:                      Pricewaterhouse Coopers 
                                           LLP 
 

There is no further information to be disclosed in relation to the director appointment pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM Rules.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNUNVNRONUVUAR

(END) Dow Jones Newswires

May 30, 2023 02:00 ET (06:00 GMT)